procyanidin has been researched along with sorafenib in 1 studies
Studies (procyanidin) | Trials (procyanidin) | Recent Studies (post-2010) (procyanidin) | Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) |
---|---|---|---|---|---|
4,116 | 136 | 2,747 | 6,520 | 730 | 5,251 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, J; Chen, K; Dai, W; Feng, J; Guo, C; Ji, J; Mao, Y; Wang, F; Wu, J; Wu, L; Xu, L; Yu, Q; Zhang, J | 1 |
1 other study(ies) available for procyanidin and sorafenib
Article | Year |
---|---|
PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma.
Topics: Active Transport, Cell Nucleus; Animals; Apoptosis; Carcinoma, Hepatocellular; Carrier Proteins; Cell Cycle Checkpoints; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glycolysis; Heterografts; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Membrane Proteins; Mice; Proanthocyanidins; Sorafenib; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2019 |